JADE2

Across TCGA pan-cancer cohorts, JADE2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated JADE2 data layer compared with 20 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher JADE2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated JADE2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where JADE2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.534	0.337	.017	19	view →
LUAD	OS	Quartile	All	0.944	0.722	.011	15	view →
UCEC	OS	Median	All	0.978	0.845	.011	2	view →
LSCC	DFS	Quartile	All	0.654	0.911	.021	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

JADE2–PDAC (DFS)

Open the PDAC breakdown →